期刊文献+

纤溶酶原激活物抑制剂-1与脑梗死相关性的研究进展 被引量:1

暂未订购
导出
摘要 纤溶酶原激活物抑制剂-1(PAI-1)是tPA和uPA的主要抑制剂。PAI-1受PAI-1 基因调控,并受多种因素的影响。PAI-1在纤溶系统中起重要作用,与脑梗死的发生、发展和恢复有着密切的关系。PAI-1抑制剂也许可以提供与抗血小板药或抗凝药不同机制的新的抗血栓药。
作者 刘洲 赵斌
出处 《神经疾病与精神卫生》 2005年第3期224-227,共4页 Journal of Neuroscience and Mental Health
  • 相关文献

参考文献32

  • 1Levi M, Biemond BJ, Van Zonneveld A J, et al. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis[J]. Circulation,1992,85(1) :305-312.
  • 2Hekman CM,Loskutoff DJ. Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator[J]. Arch Biochem Biophys,1988,262:199-210.
  • 3Loskutoff DJ,Curriden SA,Hu G,et al. Regulation of cell adhesion by PAI-1[J]. APMIS,1999,107 (1) :54-61.
  • 4Schafer K, Konstantinides S. PAI- 1 and vasculopathy: the debate continues[J]. J Thromb Haemost, 2004,2 (1): 13- 15.
  • 5Nordt TK,Lobrmann J,Bode C. Regulation of PAI- 1 Expression by Genetic Polymorphisms Impact on Atherogenesis[J]. Thromb Res, 2001,103(Sup): 1- 5.
  • 6Eriksson P,Kallin B,Van't Hooft FM,et al. Allele-specific increasein basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction[J]. Proc Natl Acad Sci USA,1995,92:1 851-1 855.
  • 7McCormack LJ,Semple JI,Stickland MH, et al. The effect of number of days in culture and plasminogen activator inhibitor-1 (PAI-1) 4G/5G genotype on PAI-1 antigen release by cultured human umbilical vein endothelial cells[J]. Thromb Res, 1998,92(5) :199-206.
  • 8Eriksson P, Nilsson L, Karpe F. Very- low- density lipoprotein response element in the promoter region of the humam plasminogen activator inhibitor- 1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia [J]. Arterioscler Thromb Vasc Biol, 1998,18 (1): 20- 26.
  • 9Menges T,Hermans PW,Little SG,et al. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients[J]. Lancet, 2001, 357 (9262):1 096-1 097.
  • 10Grenett HE,Benza RL,Li XN,et al. Expression of plasminogen activator inhibitor type Ⅰ in genotyped human endothelial cell cultures: genotype- specific regulation by insulin[J].Thromb Haemost,1999,82(5) :1 504-1 509.

同被引文献26

  • 1陈立云,王拥军,赵性泉.脑梗死后出血性转化的研究进展[J].中国卒中杂志,2006,1(12):904-906. 被引量:33
  • 2全冠民,袁涛,刘怀军.急性脑梗死出血性转化及MRI评估[J].国外医学(临床放射学分册),2006,29(5):311-314. 被引量:21
  • 3雷惠新,汪效松,张旭,程琼,周秀珍.急性脑血管病患者血浆t-PA、PAI-1活性测定及意义[J].卒中与神经疾病,2007,14(2):73-75. 被引量:5
  • 4Hamann GF,Okada Y,Fitridge R,et al.Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion[J].Stroke,1995,26(20):2 120-2 126.
  • 5Okada Y,Copeland BR,Fitridge R,et al.Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion[J].Stroke,1994,25(9):1 847-1 853.
  • 6Barr TL,Latour LL,Lee KY,et al.Blood brain barrier disruption in humans is independently associated with increased matrix metalloproteinase 9[J].Stroke,2010,41(3):e123-e128.
  • 7Machado LS,Sazonova I,Kozak A,et al.Minocycline and tissue plasminogen activator for stroke:Assessment of interaction potential[J].Stroke,2009,40(9):3 028-3 033.
  • 8Kelly MA,Shuaib A,Todd KG,et al.Matrix metalloproteinase activation and blood brain barrier breakdown following thrombolysis[J].Exp Neurol,2006,200(1):38-49.
  • 9Castellanos M,Sobrino T,Millan M,et al.Serum cellular fibronectin and matrix metalloproteinase 9 as screening biomarkers for the prediction of parenchymal hematoma after thrombolytic therapy in acute ischemic stroke:a multicenter confirmatory study[J].Stroke,2007,38(6):1 855-1 859.
  • 10Ning M,Furie KL,Koroshetz WJ,et al.Association between tPA therapy and raised early matrix metalloproteinase 9 in acute stroke[J].Neurology,2006,66(10):1 550-1 555.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部